News/Events/Local Blog

A Phase I study of the investigational CAR-T cell therapy prulacabtagene leucel (prula-cel) found that some people with SLE, including those with lupus nephritis (LN), achieved remission and kidney-related responses after a single treatment.Read more

A new study found that dietary supplement use is widespread among adults living with systemic lupus erythematosus (SLE), with more than 80% of participants reporting use of at least one supplement and more than half using two or more.Read more

A new study found that people with systemic lupus erythematosus (SLE) who also had depression, anxiety and/or post-traumatic stress disorder (PTSD) experienced higher rates of emergency department visits and hospitalizations than those without these diagnoses.Read more

Immunovant has announced topline results from a proof-of-concept study evaluating treatment imeroprubart (IMVT-1402) in people with cutaneous lupus erythematosus (CLE).Read more

A new systematic review and meta-analysis found that people with systemic lupus erythematosus (SLE) had a significantly higher risk of stroke compared with people without SLE.Read more

A new study found that non-Hispanic Black individuals with systemic lupus erythematosus (SLE) experienced the highest rates of maternal cardiovascular events, maternal adverse pregnancy outcomes and infant adverse outcomes.Read more

A new investigative therapy, afimetoran, for adults with systemic lupus erythematosus (SLE) met its primary endpoint in a Phase 2 global, double-blind, randomized, dose-ranging, placebo-controlled trial (NCT04895696), showing a clear, statistically significant, and clinically meaningful benefit. Afimetoran is a selective, oral, once-daily...Read more

A new study comparing perspectives about disease flares in people with systemic autoimmune rheumatic diseases (SARD), like systemic lupus erythematosus (SLE), and clinicians found differences in how each recognizes a flare, especially in how quickly they begin and how they are identified.Read more